Warrendale, PA – According to filings with the U.S. Securities and Exchange Commission, ECM Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Fagan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ECM Therapeutics
Advancing regenerative medicine through the development of a natural biomaterial that restores mother natures template to treat disease and injury. ECM scaffolds, in solid form, have been successfully used in more than 10 million human patients to repair a variety of body systems such as musculoskeletal tissues, cardiovascular structures, and non-healing skin wounds, among others. These products have all received FDA clearance. ECM Therapeutics? patented ECM hydrogel technology allows for expanded, less invasive applications in multiple disease areas. The first clinical product, EsophaGel, treats Barretts esophagus, a precancerous condition that currently has no effective therapy.

To learn more about ECM Therapeutics, visit http://ecmtherapeutics.com/

Contact:
Paul Fagan, Chief Executive Officer
724-242-7106
pfagan@ecmtherapeutics.com
https://www.linkedin.com/in/paul-fagan-80b072168/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved